Loading...
In two recent industry-funded studies, investigators evaluated the safety and efficacy of sofosbuvir (400 mg daily) and ribavirin (1000–1200 mg daily) for treating hepatitis C virus (HCV) infection in patients needing liver transplantation.
In a phase II, open-label study, 61 patients with Child-Pugh scores ≤7 and hepatocellular carcinoma received up to 48 weeks of the sofosbuvir-ribavirin regimen before liver transplantation. The primary endpoint was HCV RNA <25 IU/mL at 12 weeks after liver transplantation (SVR12). Of the 43 patients who underwent liver transplantation and had HCV RNA <25 IU/mL at that time, 70% achieved SVR12. The likelihood of achieving SVR12 was higher in patients with HCV RNA <25 IU/mL for ≥30 days versus <30 days pret…